Facebook picto   picto linkdink   picto tiwter


HIFU for Prostate Tissue Ablation

For more than 2 decades, EDAP TMS has been committed to bringing a non-invasive alternative to patients with prostate conditions with optimal efficacy and minimal side effects.

HIFU (High Intensity Focused Ultrasound), jointly developed in the early 1990s by Inserm (French Institute of Medical Research), HCL (Lyon University Hospitals) and EDAP TMS, has been used routinely to treat prostate cancer for more than 20 years throughout the world*. With more than 45,000 treatments performed on 3 generations of commercial devices: Ablatherm® Maxis (from 1993 to 2005), Ablatherm® Integrated Imaging (since 2005) and Focal One® (since 2013) HIFU has been used to treat prostate cancer* by creating a precise and irreversible coagulation necrosis of the targeted tissue while preserving the surrounding tissue.

HIFU Focal Ablation of Prostate


Focal One®

Focal One® brings the answer to all requirements for ideal focal HIFU ablation: accurate and MR-fused imaging, non-invasive surgical approach, as well as precise and efficient therapeutic energy.


Ablatherm® Fusion

Ablatherm® Fusion is a fully robotic device (Robotic HIFU) with innovative features that guarantee optimal safety and efficiency for each procedure. This non-invasive technology causes few side effects and helps preserve patient quality of life. It allows precise target ablation from MRI and ultrasound target localization.

* In the United States, Ablatherm®, Ablatherm® Fusion and Focal One® are cleared by the FDA and indicated for the ablation of prostate tissue. HIFU can be subject to local regulations. For more information, please contact us. HIFU can be subject to local regulations. For more information, please contact us.